Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
129 hedge funds and large institutions have $467M invested in Achillion Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 44 reducing their positions, and 18 closing their positions.
13% more capital invested
Capital invested by funds: $415M → $467M (+$52.2M)
8% more call options, than puts
Call options by funds: $1.85M | Put options by funds: $1.71M
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
1% less funds holding
Funds holding: 130 → 129 (-1)
2% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 44
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$18.2M |
| 2 |
RI
RTW Investments
New York
|
+$6.39M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.05M |
| 4 |
Millennium Management
New York
|
+$4.41M |
| 5 |
SAM
Senzar Asset Management
New York
|
+$4.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$6.49M |
| 2 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$2.1M |
| 3 |
SIM
Spark Investment Management
New York
|
-$2.07M |
| 4 |
MC
Marcus Capital
Northbrook,
Illinois
|
-$1.75M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$1.53M |
ACHN Hedge Fund Activity: Q2 2017 in Review
129 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q2 2017, worth a combined $467M — up 13% from $415M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ACHN positions and 18 closed out — a net gain of 1 holder — while 43 added to existing stakes and 44 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $18.2M. The largest seller was Morgan Stanley, cutting an estimated $6.49M.
- 129 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q2 2017, down from 130 in Q1 2017.
- Funds reported $467M of Achillion Pharmaceuticals stock for Q2 2017, up 13% quarter-over-quarter.
- 19 funds opened new Achillion Pharmaceuticals positions in Q2 2017 and 18 closed out, a net change of +1 holder.
- The largest Achillion Pharmaceuticals buyer in Q2 2017 was Janus Henderson Group, an estimated $18.2M added.
- The largest Achillion Pharmaceuticals seller in Q2 2017 was Morgan Stanley, an estimated $6.49M sold.
Based on aggregated 13F filings for Q2 2017.